The US Food and Drug Administration’s (FDA) guidance document on decentralised clinical trials (DCTs) published in September 2024 is a...

Within the trial’s community, we are regularly talking about more efficient designs such as adaptive designs and decentralising elements...

The following blog represents my personal perspective and experiences within this context. I warmly welcome any different viewpoints and...

This blog post is part of a series of posts giving an insight into the role of statisticians working on trials within the Imperial...

This blog post is part of a series of posts giving an insight into the role of statisticians working on trials within the Imperial...